SynthesisAnnals of medicine2024
Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis.
Synthesis in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pattern and associated factors of COVID-19 knowledge, attitude and practice (KAP) among COVID-19-comorbid patients: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Risk Factors for Poor Neurological Outcomes at Discharge in Tuberculous Meningitis: Disease Severity, Host Factors, and Drug Therapy.Tropical medicine and infectious disease · 2026Article
- Pulmonary cavitation as a dominant prognostic indicator in tuberculosis complicated by chronic pulmonary aspergillosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- The Shifting Landscape of HIV-Tuberculosis Co-Infection in the MENA Region with a Focus on Saudi Arabia: A Systematic Epidemiological Analysis over Three Decades.Infectious diseases and therapy · 2026Article
- Factors associated with extended treatment duration in patients with drug-susceptible pulmonary tuberculosis: a prospective multicentre cohort study in South Korea.BMC infectious diseases · 2026Article
- Gut microbiota characteristics and its biological function analysis in patients with tuberculosis and diabetes mellitus co-morbidity.BMC microbiology · 2026Article
- Methodologies for studying depression in persons with tuberculosis: A scoping review.PLOS global public health · 2026Article
- Sociodemographic and Clinical Predictors of Tuberculosis and Unsuccessful Treatment Outcomes in Davao City, Philippines: A Retrospective Cohort Study.International journal of environmental research and public health · 2025Article
- Risk factors on length of stay among pulmonary tuberculosis patients: A systematic review and meta-analysis.International journal of nursing studies advances · 2025Article
- Recent advances in biomarkers for diabetes mellitus and tuberculosis comorbidity: a comprehensive review.Frontiers in endocrinology · 2025Review
- Bibliometric analysis and knowledge mapping of diabetes mellitus combined with tuberculosis research: trends from 1995 to 2023.Frontiers in immunology · 2025Article
- Comorbidity profiles among sputum-positive tuberculosis patients in Cameroon.Frontiers in tuberculosis · 2024Article
- Optimized anti-tuberculosis duration for drug-susceptible pulmonary tuberculosis-diabetes mellitus comorbidities: study protocol for a multicenter randomized controlled trial.BMC pulmonary medicine · 2024Article
- The direct cost of chronic kidney disease (CKD) reported in Asian countries; a systematic literature review.Cost effectiveness and resource allocation : C/E · 2024Article
- Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis.Journal of pharmaceutical policy and practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.
methodsThis meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Through a systematic review of relevant literature, we focused on studies investigating treatment outcomes including extended treatment duration and recurrence for individuals with both TB and DM undergoing DOTS therapy. The extracted information included study designs, sample sizes, patient characteristics and reported treatment results.
resultsIn 44 studies from different parts of the world, the pooled HR for the impact of DM on extended treatment duration and reoccurrence were HR 0.72, 95% CI 0.56-0.83,
conclusionsA negative impact of DM was found on recurrence and extended treatment duration in TB patients treated with DOTS therapy. DM type 2 is responsible for the TB treatment prolongation and TB recurrence rates. By implementing effective management strategies and advancing research, the challenges can be mitigated, arising due to the complex interaction between DM and TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.